Relevant bibliographies by topics / Prurits

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Prurits'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 January 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Prurits.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Prurits"

1

Jaeger, Philippe. "Prurits, irritations chroniques de la peau et urticaire." Revue française de psychosomatique 29, no. 1 (2006): 51. http://dx.doi.org/10.3917/rfps.029.0051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Robert, M., L. Misery, and E. Brenaut. "Étiologie des prurits sine materia : une étude rétrospective de 197 patients." Annales de Dermatologie et de Vénéréologie 147, no. 12 (2020): A306. http://dx.doi.org/10.1016/j.annder.2020.09.458.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Smith, Payton. "Treating Chronic Pruritus: Are We at the Threshold of a Breakthrough?" SKIN The Journal of Cutaneous Medicine 8, no. 4 (2024): 1711–13. http://dx.doi.org/10.25251/skin.8.4.11.

Full text
Abstract:
Chronic pruritis, characterized by persistent itchiness lasting more than six weeks, affects up to 15% of the population, significantly impairing quality of life. Despite its prevalence and impact, there is an absence of FDA-approved medications specifically for the treatment of chronic pruritus, highlighting a significant unmet need in dermatology. Advancements in dermatologic medications, however, including the development of biologics and Janus kinase (JAK) inhibitors, signal potential breakthroughs in pruritus management through a radically different mechanism of action that focuses on their effect on the nervous system. Currently, the most commonly utilized treatments for pruritis are sedating antihistamines, which have been largely ineffective for non-histamine-induced itch, underscoring the necessity for novel approaches. This editorial reviews key studies and clinical trials with a particular focus on cases of prurigo nodularis, where itch serves as the primary pathology rather than just a symptom. The effectiveness of dupilumab in phase III trials for treating prurigo nodularis, independent of its effects on dermatitis or atopic background, alongside the success of JAK inhibitors in managing chronic idiopathic pruritus, indicates a shift towards therapies that directly and specifically target itch nerve pathways instead of indirectly via immune system modulation or sedation. These developments suggest that significant progress may be on the horizon for treating chronic itch, providing hope for those suffering from pruritis, the number one cause of misery in dermatology.
APA, Harvard, Vancouver, ISO, and other styles
4

Furue, Masutaka, and Mihoko Furue. "Interleukin-31 and Pruritic Skin." Journal of Clinical Medicine 10, no. 9 (2021): 1906. http://dx.doi.org/10.3390/jcm10091906.

Full text
Abstract:
Skin inflammation often evokes pruritus, which is the major subjective symptom in many inflammatory skin diseases such as atopic dermatitis and prurigo nodularis. Pruritus or itch is a specific sensation found only in the skin. Recent studies have stressed the pivotal role played by interleukin-31 (IL-31) in the sensation of pruritus. IL-31 is produced by various cells including T helper 2 cells, macrophages, dendritic cells and eosinophils. IL-31 signals via a heterodimeric receptor composed of IL-31 receptor A (IL-31RA) and oncostatin M receptor β. Recent clinical trials have shown that the anti-IL-31RA antibody nemolizumab can successfully decrease pruritus in patients with atopic dermatitis and prurigo nodularis. The IL-31 pathway and pruritic skin are highlighted in this review article.
APA, Harvard, Vancouver, ISO, and other styles
5

Tareen, Attiya, Irfan Ullah, Ammara Safdar, Hadia Yaqub Khan, Uzma Rajar, and Habiba Yaqub Khan. "Generalized Pruritus: An Etiological Breakup of 700 patients presenting to dermatology opd of a local hospital." BMC Journal of Medical Sciences 3, no. 2 (2023): 65–69. https://doi.org/10.70905/bmcj.03.02.049.

Full text
Abstract:
Background: Pruritus is an itching sensation or a constant urge to itch over skin that may be localized in response to a local stimulus or generalized due to an underlying condition with or without presence of causative agent. It can be caused by dermatological or systemic conditions, iatrogenic or as a response to external substances such as parasites. Generalized pruritus may not be necessarily due to dermatological causes and systemic, neurologic, endocrinologic, and psychogenic conditions may have pruritus as a primary cutaneous manifestation. Skin conditions like Scabies, eczema and airborne dermatitis are commonly incriminated as reason for intense itching and so lab workup or clinical examination and history taking is often omitted, in our busy outdoors. Therefore, the purpose of this study is to rule out underlying common systemic diseases like hypothyroidism, diabetes mellitus and chronic renal and liver disease as cause of severe generalized pruritus. Objective: To identify the underlying cause of generalized pruritus in patients presenting to dermatology outdoor excluding pruritic dermatological diseases. Methodology: This is a cross-sectional observational study conducted on 700 patients from January 2018 to October 2021, in Fauji Foundation hospital Rawalpindi. Patients between the ages of 15 to 69 years visiting dermatology OPD of the department with complaints of generalized pruritus, who were recruited for the study after filling the consent form. Clinical investigations (Blood Cp, LFTS, RFTs, TFTs) and past medical history were taken to identify the underlying cause of pruritus was conducted and diagnoses were documented Only the patients who were having non dermatological causes were included in the study and the diagnoses were further categorized as idiopathic, systemic, endocrinological, neurogenic, psychogenic and drug induced. Results were compiled and analyzed using SPSS version 22. Results: The results of this study show that 700 participants with mean age of 47.39, out of which 110 were males and 590 were females had generalized pruritus. Out of them, 126 (19%) had pruritus due to chronic renal disease, 119(17%) had chronic liver disease, 63 (9%) had diabetes mellitus, 42 (6%) had paraneoplastic, 126(18%) senile pruritis, 35(5%) had cholinergic pruritus,21 (3%) iron deficiency anemia. 14(2%) had atopic dermatitis of elderly. Drug induced pruritus 56(8%). Conclusion: Pruritus without known pruritic dermatoses is a common presenting complaint in patients presenting to outdoors having one of the underlying systemic disease. Further work is needed to evaluate impact of pruritus on quality of life in these already diseased patients.
APA, Harvard, Vancouver, ISO, and other styles
6

Garcovich, Simone, Martina Maurelli, Paolo Gisondi, Ketty Peris, Gil Yosipovitch, and Giampiero Girolomoni. "Pruritus as a Distinctive Feature of Type 2 Inflammation." Vaccines 9, no. 3 (2021): 303. http://dx.doi.org/10.3390/vaccines9030303.

Full text
Abstract:
Pruritus is a common symptom of several skin diseases, both inflammatory and neoplastic. Pruritus might have a tremendous impact on patients’ quality of life and strongly interfere with sleep, social, and work activities. We review the role of type-2 inflammation and immunity in the pathogenesis of chronic pruritic conditions of the skin. Type 2 cytokines, including IL-4, IL-13, thymic stromal lymphopoietin, periostin, IL-31, IL-25, and IL-33 are released by mast cells, innate lymphoid cells 2, keratinocytes, and type 2 T lymphocytes, and are master regulators of chronic itch. These cytokines might act as direct pruritogen on primary sensory neurons (pruriceptors) or alter the sensitivity to other itch mediators Type 2 inflammation- and immunity-dominated skin diseases, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, scabies, parasitic diseases, urticaria, and Sézary syndrome are indeed conditions associated with most severe pruritus. In contrast, in other skin diseases, such as scleroderma, lupus erythematosus, hidradenitis suppurativa, and acne, type 2 inflammation is less represented, and pruritus is milder or variable. Th2 inflammation and immunity evolved to protect against parasites, and thus, the scratching response evoked by pruritus might have developed to alert about the presence and to remove parasites from the skin surface.
APA, Harvard, Vancouver, ISO, and other styles
7

Fölster-Holst, Regina, Rahel Reimer, Claudia Neumann, et al. "Comparison of Epidermal Barrier Integrity in Adults with Classic Atopic Dermatitis, Atopic Prurigo and Non-Atopic Prurigo Nodularis." Biology 10, no. 10 (2021): 1008. http://dx.doi.org/10.3390/biology10101008.

Full text
Abstract:
A deficient epidermal barrier is a key feature of atopic dermatitis (AD) and comprises altered lipid and protein content and composition of the stratum corneum resulting in disturbed water balance. Clinically, eczematous lesions on dry skin and pruritus develop. Pruritic nodules occur in prurigo nodularis (PN), another chronic skin disease, which can be associated with atopy. We aimed at comparing the three clinical pictures, classic AD, atopic prurigo (AP), and non-atopic PN, to healthy controls regarding the epidermal barrier. We determined clinical parameters and performed biophysical measurements, histology/immunohistochemistry, electron microscopy, and molecular biological analysis. We found distinctively elevated clinical scores, reduced hydration and increased transepidermal water loss, epidermal hyperplasia and inflammation reduced filaggrin and increased loricrin and involucrin expression, as well as reduced intercellular lipid lamellae in all three disease groups. These findings show a severe disruption in epidermal barrier structure and function in all three disorders so that epidermal barrier impairment is now proven not only for AD but also for PN.
APA, Harvard, Vancouver, ISO, and other styles
8

Dumont, Shireen, Marc Péchère, and Laurence Toutous Trellu. "Chronic Prurigo: An Unusual Presentation of Hodgkin Lymphoma." Case Reports in Dermatology 10, no. 2 (2018): 122–26. http://dx.doi.org/10.1159/000489161.

Full text
Abstract:
Background: Prurigo nodularis is a condition of unknown origin defined by papulonodular eruption and intense pruritus. Hodgkin lymphoma often presents nonspecific initial symptoms. An association between systemic malignancy and cutaneous manifestations has long been documented. We report a case of prurigo nodularis as a first presentation of Hodgkin lymphoma. Case: A 35-year-old woman presented with a 2-year history of pruritus. Previously diagnosed with bedbugs, the pruritus persisted even after insect eradication, with the appearance of papulonodular lesions consistent with chronic prurigo. The pruritus and the pain were refractory to all treatments. She had no past medical history or clinical, radiological, or laboratory findings. A lymphadenopathy was revealed 2 years after onset of the symptoms. Lymph node biopsy showed a nodular sclerosis Hodgkin lymphoma. The patient was initiated on chemotherapy and the skin lesions decreased. Conclusion: This case report of chronic prurigo as the first manifestation of a systemic malignancy reminds us of the importance of a systematic diagnostic approach to this kind of patients initially and throughout time, especially if the symptoms do not respond to treatment. Our case may question the role of imaging examinations in the management and follow-up of a persistent prurigo nodularis.
APA, Harvard, Vancouver, ISO, and other styles
9

Chung, Bo Young, Ji Young Um, Seok Young Kang, et al. "Oral Alitretinoin for Patients with Refractory Prurigo." Medicina 56, no. 11 (2020): 599. http://dx.doi.org/10.3390/medicina56110599.

Full text
Abstract:
Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging. Conventional systemic treatments may be beneficial; however, their possible side effects and possible transient efficacy is still a problem. We aimed to present the clinical course and effect of treatment with alitretinoin on patients with prurigo nodularis initially treated with conventional treatments like oral antihistamine, cyclosporine, and phototherapy. Methods: all the patients had prurigo nodularis refractory to conventional treatment. Their medical records included demographic features, past medical history, duration of disease, and treatment modalities; and the clinical courses of the patients were reviewed for this retrospective study. We evaluated patient pruritus and skin lesions for the duration. Results: we present reports involving 10 patients with refractory prurigo. All the patients in our cases were treated with oral alitretinoin after previous treatments and reported the improvement of skin lesions and pruritus within 2 weeks to 3 months. Conclusions: we suggest that oral alitretinoin may be an effective and well tolerated treatment option for patients with intractable prurigo. Further clinical studies are warranted to confirm the long-lasting efficacy and safety of alitretinoin for treating patients with prurigo.
APA, Harvard, Vancouver, ISO, and other styles
10

Ferreira, Bárbara R., and Laurent Misery. "Psychopathology Associated with Chronic Pruritus: A Systematic Review." Acta Dermato-Venereologica 103 (August 22, 2023): adv8488. http://dx.doi.org/10.2340/actadv.v103.8488.

Full text
Abstract:
There are no previous studies of the psychopathology associated with different aetiologies of chronic pruritus. A systematic review was performed of cohort and case-control studies comparing healthy controls with patients with chronic pruritus related to primary dermatoses, systemic diseases, psychogenic pruritus, idiopathic pruritus, prurigo nodularis and/or lichen simplex chronicus. The review was registered in PROSPERO and performed according to the PRISMA statement, which allowed the inclusion of 26 studies. The quality of eligible studies was assessed using the modified Newcastle-Ottawa Scale. Most of the studies concern primary dermatoses and systemic diseases. Sleep disorders are a common comorbidity interrelated with pruritus, anxiety and depressive symptoms, in primary dermatoses. Sleep disorders are linked with pruritus and depressive symptoms in end-stage renal disease and hepatobiliary disease. Depressive and anxiety symptoms are associated with psychogenic pruritus. Psychogenic pruritus, lichen simplex chronicus and some primary dermatoses are linked with personality characteristics. Further studies are required to explore in depth the psychopathology linked with psychogenic pruritus and prurigo nodularis, as well as psychopathology linked with other primary dermatoses and systemic disorders associated with chronic pruritus, and to better differentiate psychogenic pruritus from psychopathological characteristics linked with other aetiologies of chronic pruritus, in order to improve the management of patients with chronic pruritus.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Prurits"

1

Najafi, Peyman. "Mécanismes centraux du prurit chronique : imagerie cérébrale fonctionnelle et structurelle." Thesis, Brest, 2020. http://www.theses.fr/2020BRES0004.

Full text
Abstract:
Malgré les progrès récents enregistrés dans le domaine de la démangeaison, les mécanismes centraux sous-jacents et toutes les possibles perturbations causées par certaines pathologies sont relativement peu connues. Il est possible d’induire une démangeaison par simple visionnage d’une tierce personne en train de se gratter. On appelle cela le prurit contagieux dont le mode d’activation est connu pour mettre en jeu un réseau neuronal similaire à celui observé dans le prurit pathologique ou chimiquement induit. Nous avons recruté 15 volontaires sains, 14 patients psoriasiques et 2 urticaire auxquels nous avons diffusé ces vidéos tout en enregistrant leurs activités cérébrales par IRMf. Nous avons également mesuré la connectivité structurale par tenseur de diffusion pour les deux groupes. Nos résultats démontrent que le réseau cérébral qui prend en charge l’information de démangeaison dans notre cerveau est plus connecté chez les patients psoriasiques que chez les volontaires sains pour des niveaux de démangeaison induits équivalents. Par ailleurs, l’augmentation de la connectivité structurale reflète que les aspects perceptivo-moteur du grattage et de son contrôle induisent des changements à long terme sur la connectivité cérébrale des patients<br>Despite recent advances in studying itch, central mechanisms underlying its perception and any possible disruption to them caused by pathologies are relatively unknown. Herein we have studied central mechanism of itch perception in two pathologies Psoriasis and Urticaria (to a smaller degree), while comparing them to a healthy control group. For this goal 14 psoriasis patients, 15 healthy control and 2 Urticaria subjects were recruited. Itch was mentally induced in subjects during their MRI session by videos showing others scratching themselves; a phenomenon known as contagious itch. fMRI, DTI and anatomical images were acquired during this study. Our results show that parts of the brain network that is tasked with itch perception is more interconnected in psoriatic patients compared to healthy volunteers for equivalent levels of induced itch. In addition, the increase in structural connectivity reflects that the perceptual-motor aspects of scratching and its hyperactivity can induce long-term changes in patients' brain’s white matter microstructure
APA, Harvard, Vancouver, ISO, and other styles
2

Roque, Cunha Ferreira Bárbara Isabel. "Prurit psychogène." Electronic Thesis or Diss., Brest, 2024. http://www.theses.fr/2024BRES0058.

Full text
Abstract:
Le prurit psychogène est un diagnostic distinct chez les patients souffrant de prurit chronique et concerne les patients sans dermatose primaire ou une affection systémique liée au prurit chez qui des facteurs psychogènes sont identifiés. Ces patients peuvent présenter un stress psychique, une dynamique psychosociale ou une psychopathologie qui pourraient être à l’origine du prurit. Le groupe français de psychodermatologie a proposé des critères pour le diagnostic : 3/3 obligatoires et au moins 3/7 optionnels. Alors que les classifications disponibles ne permettent pas d’identifier les caractéristiques psychologiques et la psychopathologie associées, aucune étude prospective n’a été réalisée jusqu’à présent sur ce sujet. Nous avons donc fait une étude avec des patients diagnostiqués avec un prurit psychogène, en les comparant avec des patients souffrant de prurit chronique dû à d’autres étiologies. Certaines caractéristiques psychosociales liées au prurit psychogène permettent de le différencier des autres types de prurit, en particulier, des scores plus élevés d’alexithymie, d’anxiété, d’expériences dissociatives, sur l’échelle de stress de Holmes et Rahe les derniers 24 mois et de certaines stratégies de coping dysfonctionnelles. L’analyse des données souligne l’importance de considérer la présence d’une dynamique psychologique liée au contexte socio-familial du patient, renforçant la pertinence d’une approche psychodermatologique appliquée au prurit chronique et permettant d’identifier cette population de patients, dont l’approche thérapeutique devrait donner la priorité à l’approche du lien entre cette dynamique psychosociale et l’évolution des symptômes<br>Psychogenic pruritus is a distinct diagnosis in patients with chronic pruritus which refers to patients without a primarydermatosis or systemic disorder related to pruritus in whom psychogenic factors are identified. These patients may present with psychological stress, a psychosocial dynamic and psychopathology that could be at the origin of pruritus. The French psychodermatology group has proposed criteriafor diagnosis : 3/3 mandatory and at least 3/7 optional. As the available classifications do not allow for the identification of associated psychological characteristics and psychopatholoy, no prospective studies have yet been conducted on this subject. A prospective study was performed on patients diagnosed with psychogenic pruritus, compraing themwith patients suffering from chronic pruritus due to other disorders. There are some psychosocial characteristics associated with psychogenic pruritus, allowing it to be differentiated from other types of chronic pruritus, in particular, higher scores of alexithymia, anxiety and dissociative experiences, as welle as higher scores on the Holmes and rabe stress scale the last 24 mo,nths and certain dysfunctional coping strategies. Analysis of the data underlines the importance of considering the rpesence of a psychological dynamic linked to the patient’s socio-familial context, reinforcing the relevanceof a psychodermatological approach applied to chronic pruritus, making it possible to identify this population of patients, whose therapeutic approach should give priority to addressing the link between these psychosocial dynamics and the evolution of symptoms
APA, Harvard, Vancouver, ISO, and other styles
3

Bertrand, Anne. "Physiopathologie et traitement du prurit." Paris 5, 1998. http://www.theses.fr/1998PA05P114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bergeret, Laure. "Etude en TEP - H215O, des bases cérébrales de la sensation prurigineuse, induite par la technique d'iontophorèse à l'histamine et de sa modulation par une tâche cognitive." Toulouse 3, 2010. http://thesesups.ups-tlse.fr/880/.

Full text
Abstract:
Le prurit est le symptôme de nombreuses maladies dermatologiques ou systémiques et sa physiopathologie est encore mal connue. Nous nous sommes intéressés ici à son étude en neuroimagerie en étudiant par imagerie TEP à l'H215O, les activations cérébrales liées à un prurit induit par la technique d'iontophorèse à l'histamine et sa modulation par une tâche cognitive (tâche de Stroop). La première partie du travail permettait de vérifier que la technique d'iontophorèse à l'histamine utilisée pour l'induction de la sensation prurigineuse convenait à une étude en TEP. Dans la deuxième partie, en imagerie TEP-H215O, un réseau d'aires déjà connues comme impliquées dans la sensation prurigineuse et mis en avant. Ces aires voient leur activation modifiée lorsque l'on rajoute une tâche cognitive. L'étude en connectivité effective a permis de construire un réseau orienté afin d'approfondir nos résultats d'imagerie<br>Chronic itch occurs as a life-distressing symptom of many systemic and skin diseases and is also a frequent symptom in the general population. The physiopathotology of this sensation is still unclear. The purpose of the study was assessment of the cerebral response to itch induced by histamine iontophoresis and show any central modulation of the cortical network involved in itch sensation by a cognitive task, the Stroop task, with PET H215O. Firstly, we have validated the stimulation parameters of our histamine iontophoresis model for itch induction consistent with PET- H215O requirements. Consequently, the model was used in a positron emission topography study and the resulting areas of brain activation were in agreement with previously published studies of this kind. Under Stroop condition the intensity of itching stimulus decreases and the pattern of activation was changed. Periaqueductal grey matter (PAG) seems to be involved in itch modulation. We completed our study by an effective connectivity study that allows us to make an oriented network
APA, Harvard, Vancouver, ISO, and other styles
5

Badiaga, Sékéné. "Stratégies de surveillance et de prévention des ectoparasitoses et de ses complications dans les populations sans domicile fixe." Aix-Marseille 2, 2008. http://www.theses.fr/2008AIX20707.

Full text
Abstract:
Les conditions de vie précaires des personnes sans domicile fixe ainsi que leurs difficultés d’accès aux soins favorisent les maladies infectieuses. A Marseille, nous avons mis en place une stratégie de surveillance et de contrôle des infections cutanées et de leurs complications dans cette population. Des interventions ponctuelles annuelles ont été menées dans les centres d’hébergement. Nous avons observé une prévalence significativement plus élevée des poux de corps, de la gale, du prurit et des surinfections cutanées bactériennes. Un cas de typhus épidémique autochtone a été détecté chez une personne sans domicile fixe, alertant sur le risque d’une épidémie dans cette population. Les méthodes classiques de traitement des ectoparasitoses étant inefficaces dans les centres d’hébergement, nous avons évalué l’effet de l’ivermectine. Nous avons d’abord démontré dans une étude pilote l’efficacité transitoire de l’ivermectine dans le traitement de la pédiculose corporelle humaine dans un groupe de personnes sans domicile fixe d’un centre d’hébergement. Nous avons ensuite démontré dans une essai clinique randomisé, double aveugle et versus placebo, l’efficacité transitoire d’une dose unique d’ivermectine sur la réduction du prurit dans cette population. Ces résultats permettent d’émettre l’hypothèse qu’une administration systématique d’ivermectine (si possible associée aux mesures classiques) à toute personne sans domicile fixe se plaignant de prurit pourrait entraîner une réduction significative des ectoparasites et de leurs conséquences dans cette population. D’autres études sont nécessaires pour vérifier cette hypothèse<br>Because of poor living conditions and limited access to health care systems, homeless persons are exposed to infectious diseases. In Marseille, we implemented a strategy in order to survey and prevent skin infections and its complications in the homeless. Yearly snapshot interventions in shelters were performed. These interventions contributed to determine a significant high prevalence of body louse infestation, scabies, pruritus and bacterial skin superinfections. In addition, an acute autochthonous case of epidemic typhus was detected in a homeless person in Marseille, highlighting the threat of an outbreak of epidemic typhus for this population. As poor living conditions in shelters limit efficacy of classic therapeutic measures for these ectoparasitism, we evaluated the interest of ivermectin for the treatment of ectoparasitism in sheltered homeless. First, we demonstrated in a pilot study the transient efficacy of ivermectin against body louse infestation in a sample of sheltered homeless. Later, we demonstrated in a randomized double-blind, placebo-controlled trial, a transient efficacy of a single dose of oral ivermectin on reducing the ectoparasite-based pruritus in a sheltered homeless population. These results permit to hypothesize that systematic repeated treatments of ectoparasite-based pruritus (if possible in association with classic therapeutic measures) in the homeless is an efficient option to reduce significantly ectoparasitism and its complications in this population. Further studies are required to assess this hypothesis
APA, Harvard, Vancouver, ISO, and other styles
6

Ferreira, Jéssica Letícia Alves. "Clínica e cirurgia de pequenos animais." Master's thesis, Universidade de Évora, 2020. http://hdl.handle.net/10174/27978.

Full text
Abstract:
O presente relatório foi realizado no âmbito dos estágio curricular do Mestrado Integrado em Medicina Veterinária da Universidade de Évora e inclui duas partes. A primeira parte diz respeito à casuística acompanhada ao longo de quatro meses de estágio no Hospital Veterinário da Madeira, tendo-se iniciado a 1 de fevereiro de 2019 e terminado a 31 de maio de 2019. A segunda parte aborda uma monografia sobre o tema “Principais causas de prurido no paciente felino”, acompanhada por dois casos clínicos assistidos durante o estágio. O prurido nos gatos constitui uma condição desafiadora na prática clínica, tanto para o médico veterinário como para o tutor por manifestar-se com aumento dos comportamentos de limpeza e por ter várias etiologias. As hipersensibilidades, dermatofitose, causas parasitárias bem como alterações psicogénicas representam causas pruriginosas frequentes nesse paciente, devendo a abordagem diagnóstica ser sistemática para evitar falsos diagnósticos e ser instituído uma terapêutica adequada; ABSTRACT: Small Animal Medicine and Surgery The present report refers to the curricular internship of the Master Degree in Veterinary Medicine of the University of Évora and it is composed of two sections. The first section describes the clinical cases accompanied throughout the internship at the Hospital Veterinário da Madeira, from February 1st to May 31st, 2019. The second section consists of a bibliographic review regarding the common causes of itching in the feline patient and is followed by two clinical reports/cases followed by the trainee. Pruritus in cats is a real challenge in clinical practice, for both veterinarian and curator as it may have several etiologies and often manifests by overgrooming, which is also far from being pathognomonic. Hypersensitivity, dermatophytosis, parasitic causes as well as psychogenic disorders are common causes of itching in cats, hence a systematic diagnostic approach is needed to achieve a positive diagnosis, aiming and effective therapy.
APA, Harvard, Vancouver, ISO, and other styles
7

Silva, Maria Alice Barreiros Martins da. "Avaliação do uso de lokivetmab (Cytopoint) na dermatite atópica canina." Master's thesis, Universidade de Lisboa, Faculdade de Medicina Veterinária, 2019. http://hdl.handle.net/10400.5/18362.

Full text
Abstract:
Dissertação de Mestrado Integrado em Medicina Veterinária<br>A dermatite atópica canina (DAc) é uma doença extremamente prevalente, com uma fisiopatologia complexa que pode levar a manifestações clínicas diversas e respostas diferentes às opções terapêuticas disponíveis. O prurido é o sinal clínico mais comum desta doença, promovendo uma diminuição significativa na qualidade de vida tanto dos animais como das famílias onde estão inseridos. A IL-31 é uma citocina com um papel importante na fisiopatologia da DAc, em particular na indução do prurido. O lokivetmab é um anticorpo monoclonal caninizado contra a IL-31, cuja utilização está indicada para o tratamento das manifestações clínicas da DAc. O presente estudo teve como objetivos a avaliação da eficácia do lokivetmab no tratamento da DAc e da segurança associada à sua utilização. Os 18 animais incluídos na amostra foram sujeitos a duas administrações de lokivetmab, com um intervalo de quatro semanas. Realizaram-se avaliações repetidas do grau de prurido (obtidas pelos cuidadores com recurso a uma escala visual) e das lesões cutâneas (classificadas por um médico veterinário com base no CADESI-4) dos animais ao longo de dois meses. A segurança do lokivetmab foi investigada por comparação dos resultados das análises sanguíneas realizadas no início e no fim do tratamento e pela análise dos efeitos adversos. Considerou-se como melhoria clinicamente significativa, tanto no grau de prurido como para o CADESI-4, uma redução dos valores em pelo menos 50%. O tratamento com lokivetmab levou à melhoria do grau de prurido em 76,47% dos cães da amostra. A sua ação na diminuição do grau de prurido pôde ser observada ao fim de 24 horas e manteve-se durante pelo menos quatro semanas na maioria dos animais. A melhoria clinicamente significativa nos valores de CADESI-4 verificou-se em 77,78% dos animais. Ao fim de duas semanas de tratamento, o efeito do lokivetmab já era evidente na redução dos valores do CADESI-4, que se mantiveram baixos até ao final dos dois meses. Tanto para o grau de prurido como para o CADESI-4, apesar de não se ter verificado uma redução de pelo menos 50% nos valores destes parâmetros na totalidade da amostra, observou-se a diminuição dos valores em todos os cães à exceção de um em cada uma das avaliações. Contudo, estes dois animais mantiveram-se controlados com valores baixos durante os dois meses. Não se verificaram alterações com significado clínico nas análises sanguíneas e registaram-se apenas três casos de vómito, sendo que um foi acompanhado de diarreia, que se resolveram sem necessidade de intervenção por parte do médico veterinário. As reduções estatisticamente significativas que se observaram tanto no grau de prurido como no valor do CADESI-4 ao longo de dois meses comprovam a eficácia do lokivetmab nesta doença. Do mesmo modo, a ausência de efeitos secundários com significado clínico dá ênfase à segurança desta opção terapêutica e promovem confiança na sua utilização. O lokivetmab apresenta-se, assim, como uma excelente opção terapêutica dada a sua elevada eficácia e segurança.<br>ABSTRACT - EVALUATION OF THE USE OF LOKIVETMAB (CYTOPOINT) IN CANINE ATOPIC DERMATITIS - Canine atopic dermatitis (cAD) is an extremely prevalent disease, with a complex pathogenesis that can lead to diverse clinical manifestations and different response to the available therapeutic options. Pruritus is the most common clinical sign of this condition, significantly diminishing the animals’ and their owners’ quality of life. IL-31 is a cytokine with an important role in the pathogenesis of cAD, particularly in inducing pruritus. Lokivetmab is a caninized monoclonal antibody against IL-31, with its usage recommended for the treatment of the clinical manifestations of cAD. This study aims to evaluate the efficacy of lokivetmab in the treatment of cAD and the safety of its usage. The 18 animals enrolled were subjected to two injections of lokivetmab, within a four-week interval. The level of pruritus was continuously assessed (by the animals’ owners using a validated visual scale) and skin lesions (classified by veterinary clinicians using CADESI-4) over a period of two months. The safety of lokivetmab was investigated comparing the blood test results performed at the beginning and ending of the treatment and by evaluating adverse effects. A significant clinical improvement was defined as a 50% reduction of both pruritus and the CADESI-4 values. The treatment with lokivetmab lead to the improvement of the level of pruritus by 76.47% of the sample’s dogs. Its role in diminishing the pruritus could be observed after 24 h and continued throughout at least four weeks in most animals. The significant clinical improvement of the CADESI-4 levels was registered in 77.78% of the animals. After two weeks of treatment, the effect of lokivetmab was already evident in the reduction of CADESI-4 values, that were kept low until the end of the two-month period. Even though a reduction of at least 50% in the whole sample was not registered for both the pruritus level and the CADESI-4, a reduction of values was observed in all but one dog in each evaluation. However, these two animals maintained low levels throughout the two months. No significant clinical alterations were noticed in the blood tests, and only three cases of vomiting were registered, one of them followed by diarrhea, which resolved without clinical intervention. The statistically significant reductions that were observed, of both the level of pruritus and the value of the CADESI-4 throughout the two months, prove lokivetmab’s efficacy when treating this condition. At the same time, the absence of side effects with significant clinical importance, highlight the safety of this therapeutic option and promote trust in its use. Therefore, lokivetmab presents itself as an excellent therapeutic option due to its high efficacy and safety.<br>N/A
APA, Harvard, Vancouver, ISO, and other styles
8

Martins, Débora Margarida Moreira. "Clínica médica e cirúrgica em animais de companhia." Master's thesis, Universidade de Évora, 2017. http://hdl.handle.net/10174/21309.

Full text
Abstract:
O presente relatório refere-se a cinco meses de estágio curricular realizado no hospital veterinário CasVet. Numa primeira parte são apresentadas as instalações e descritas as atividades médico-veterinárias realizadas e assistidas, a segunda corresponde a uma revisão bibliográfica referente a dermatite atópica canina e, finalmente, a discussão de um caso clínico. Esta dermatopatia ocorre em animais predispostos geneticamente. Desenvolve-se hipersensibilidade a antigénios ambientais, apresentando prurido intenso. O diagnóstico baseia-se numa boa história pregressa, exame clínico e exclusão de outras dermatopatias pruriginosas, contando com possíveis infeções secundárias. Abordagem sintomatológica, evição alergénica, melhoria da condição cutânea e imunoterapia específica constituem as medidas terapêuticas preconizadas. O caso clínico apresentado refere-se a um cão com esta dermatopatia, associada a infeção secundária e intolerância alimentar, tendo sido realizadas diversas provas para confirmação do diagnóstico e posterior controlo dietético e tratamento sistémico; Abstract: Canine atopic dermatitis This report refers to a five monthcurricular internship developed at the veterinary hospital CasVet. The first part presents the hospital facilities and describes the veterinary medical activities performed and assisted, the second part corresponds to a bibliographical review concerning canine atopic dermatitis and, in the last part, the discussion of a clinical case. This dermatopathy occurs in genetically prone animals. A hypersensitivity to environment antigens arises, thus presenting intense pruritus. The diagnosis is based on a good clinical history, clinical exams and the exclusion of other pruritic skin diseases, counting on possible secondary infections. A symptomatic approach, allergenic avoidance, improvement of the skin condition and specific immunotherapy are the recommended therapeutic measures. The clinical case presented refers to a dog with the aforementioned dermatopathy, associated with a secondary infection and food intolerance. Several tests were performed to confirm the diagnosis and subsequent dietary control and systemic treatment was prescribed.
APA, Harvard, Vancouver, ISO, and other styles
9

Martins, Anabela dos Santos. "Utilização clínica de oclacitinib no maneio da dermatite atópica canina : avaliação da resposta ao tratamento na perspetiva dos tutores." Master's thesis, Universidade de Lisboa, Faculdade de Medicina Veterinária, 2017. http://hdl.handle.net/10400.5/14332.

Full text
Abstract:
Dissertação de Mestrado Integrado em Medicina Veterinária<br>O oclacitinib (Apoquel®) é um inibidor seletivo da enzima Janus cinase (JAK), utilizado no controlo do prurido em cães com dermatite de origem alérgica, incluindo a dermatite atópica. Visto ser um fármaco recente, as informações relativas à sua utilização na prática clínica poderão complementar os conhecimentos sobre a sua eficácia e segurança a curto e longo prazo. Também é importante averiguar a opinião e o grau de satisfação dos tutores dos animais com esta nova opção terapêutica. No presente estudo, realizado no serviço de Dermatologia e Imunoalergologia do Hospital Escolar Veterinário, da Faculdade de Medicina Veterinária, da Universidade de Lisboa, avaliou-se a resposta de uma amostra de cães com dermatite atópica (DAc) ao tratamento com oclacitinib, tendo em consideração a perceção dos seus tutores. A avaliação foi realizada através da determinação do grau de prurido antes e 28 dias após o início do tratamento e da realização de um questionário aos tutores referente à resposta ao tratamento e à qualidade de vida durante o mesmo. O oclacitinib foi utilizado no âmbito de uma terapêutica multimodal e revelou ser bastante eficaz no controlo do prurido. Foram avaliados 40 cães, nos quais o grau de prurido médio passou de um valor inicial de 6,6 (prurido moderado) para 3,2 (prurido ligeiro), com 85% dos animais (34/40) a apresentarem um prurido ligeiro a muito ligeiro na fase de manutenção do tratamento. Para 90% dos tutores (36/40) o seu animal melhorou muito, 77,5% (31/40) concordaram que o tratamento com oclacitinib é eficaz e um igual número (77,5%, 31/40) discordou que este fármaco causou efeitos secundários ao seu cão. No entanto, 3 a 7 meses após o início do tratamento registou-se o aparecimento de nódulos cutâneos ou subcutâneos em 15% dos animais (6/40). O grau de satisfação dos tutores com esta terapêutica foi notório, com 92,5% (37/40) a revelarem-se satisfeitos ou muito satisfeitos com o oclacitinib. Porém, o custo do medicamento é um aspeto que os preocupa. O impacto negativo da DAc na qualidade de vida dos animais afetados e dos seus tutores continuou a estar presente durante o tratamento, mas pareceu ser atenuado por influência do oclacitinib, sugerindo uma melhoria na qualidade de vida. Tanto quanto sabemos, este é o primeiro estudo sobre a utilização clínica do oclacitinib realizado em Portugal. Neste estudo, demonstrámos a eficácia e segurança deste tratamento a curto prazo e a satisfação dos tutores com o mesmo.<br>ABSTRACT - Oclacitinib (Apoquel®) is a selective inhibitor of the Janus kinase (JAK) enzyme and it’s used for pruritus control in dogs with allergic dermatitis, including atopic dermatitis. As a new drug, information on its use in clinical practice may complement knowledge of its efficacy and safety in short and long term. It’s also important to assess the owner’s opinion and level of satisfaction with this new therapeutic option. In the present study, carried out by the Department of Dermatology and Immunoallergology from Hospital Escolar Veterinário, Faculdade de Medicina Veterinária, Universidade de Lisboa, dogs with atopic dermatitis (cAD) were evaluated regarding their response to oclacitinib treatment, considering owners’ perception. This was achieved through the determination of pruritus scores before and 28 days after starting the therapy and by an owner’s survey regarding dogs’ response to treatment and the quality of life during the same. Oclacitinib was used in a multimodal approach and shown to be very effective for pruritus reduction. Forty dogs were evaluated and initially the sample’s mean degree of pruritus was 6.6 (moderate itching), which decreased to 3.2 (mild itching), with 85% of the animals (34/40) presenting a mild to very mild itching in the maintenance phase of the treatment. For 90% of the owners (36/40) their animal improved greatly, 77.5% (31/40) agreed that oclacitinib is effective and an equal number (77.5%, 31/40) disagreed that this drug caused side effects to their dog. However, 3 to 7 months after starting the treatment, skin nodules appeared in 15% of the animals (6/40). Owners’ level of satisfaction with therapy was also evident, with 92.5% of them (37/40) being satisfied or very satisfied with oclacitinib. However, drug’s cost is an aspect that worries owners. During treatment, negative impact of cAD on the quality of life of affected animals and their owners was still present, but it appeared to be attenuated by oclacitinib, suggesting an improvement in the quality of life. To our knowledge, this is the first study on the clinical use of oclacitinib in Portugal. We have demonstrated the efficacy and safety of this treatment in the short-term and the overall owner's satisfaction.<br>N/A
APA, Harvard, Vancouver, ISO, and other styles
10

Gobo-Oliveira, Mariele. "Gabapentina versus dexclorfeniramina no tratamento do prurido urêmico de pacientes sob hemodiálise um ensaio clínico randomizado, duplo-cego e controlado /." Botucatu, 2017. http://hdl.handle.net/11449/152570.

Full text
Abstract:
Orientador: Luciana Patrícia Fernandes Abbade<br>Resumo: O prurido urêmico é uma complicação frequente em pacientes renais crônicos, com impacto na qualidade de vida. Sua etiopatogênese é multifatorial e as evidências para o tratamento com emolientes, anti-histamínicos orais e drogas de ação no sistema nervoso central, como a gabapentina, são limitadas. Objetivos: 1- verificar a prevalência de prurido urêmico e seus fatores associados; 2- avaliar a eficácia na redução do prurido urêmico com a terapia tópica com cold cream após 15 dias e 3-comparar a eficácia e segurança da gabapentina versus dexclorfeniramina na redução do prurido urêmico em um período de 21 dias. Métodos: A pesquisa foi realizada entre abril de 2014 a fevereiro de 2016. Inicialmente para atender ao objetivo 1, foi realizado estudo transversal e prospectivo com pacientes em hemodiálise (etapa 1). Os dados foram obtidos por meio de prontuário eletrônico e pela aplicação de questionário estruturado. Os pacientes que relataram prurido foram convidados a participar da etapa 2 para atender ao objetivo 2, sendo este uma série de casos com seguimento longitudinal não-comparativo, no qual os pacientes receberam cold cream para uso por 15 dias. Foram avaliados a intensidade do prurido através da Escala Visual Analógica (EVA), qualidade de vida (DLQI), número de topografias corporais afetadas, período do prurido e relatório de efeitos adversos. Ao final desta fase, para atingir o objetivo 3, os pacientes (60) que ainda se queixavam de prurido de qualquer intensidade iniciara... (Resumo completo, clicar acesso eletrônico abaixo)<br>Abstract: Uremic pruritus is a frequent complication in chronic renal patients, with an impact on quality of life. Its etiopathogenesis is multifactorial and as evidence for treatment with emollients, oral antihistamines and drugs with central nervous system action such as gabapentin are limited. Objectives: 1- to verify the prevalence of UP and its associated factors; 2- evaluate the effectiveness in reduction of uremic pruritus with topical therapy with cold cream after 15 days and 3- evaluate the efficacy and safety of gabapentin vs. dexchlorpheniramine in reducing the uremic pruritus after 21 days. Methods: The study was carried out between April 2014 and February 2016. Initially to reach objective 1, a cross-sectional and prospective study was performed with patients undergoing hemodialysis (stage 1). The data were obtained by electronic medical record and by the application of a structured questionnaire. Patients who reported pruritus were invited to participate in stage 2 to reach objective 2, a series of cases with non-comparative longitudinal follow-up, in which the patients received cold cream for apply for 15 days. The intensity of pruritus was evaluated by the Visual Analogue Scale (VAS), and also the quality of life questionnaire (DLQI), number of affected topographies, pruritus period and adverse effects were assessed. At the end of this phase, to reach the objective 3, patients (60) with any intensity of pruritus were included in stage 3, where they were randomized to re... (Complete abstract click electronic access below)<br>Doutor
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Prurits"

1

Misery, Laurent, and Sonja Ständer, eds. Pruritus. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-33142-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Misery, Laurent, and Sonja Ständer, eds. Pruritus. Springer London, 2010. http://dx.doi.org/10.1007/978-1-84882-322-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

1952-, White Stephen D., ed. Pruritus. Saunders, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sonja, Ständer, ed. Pruritus. Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Trotter, Shannon C., and Austin Cusick, eds. Clinical Cases in Pruritus. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-66274-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zbigniew, Zylicz, Jones E. Anthony, and Twycross Robert G, eds. Pruritus in advanced disease. Oxford University Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

D, Bernhard Jeffrey, ed. Itch: Mechanisms and management of pruritus. McGraw-Hill, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pandey, A. K. Velvet bean: Mucuna pruriens (L.) DC. Agrotech Publishing Academy, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gil, Yosipovitch, ed. Itch: Basic mechanisms and therapy. M. Dekker, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pras, Niesko. Bioconversion spectrum and related kinetic aspects of entrapped cells of Mucuna pruriens L. Rijksuniv., 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Prurits"

1

Ständer, Sonja. "Pruritus und Prurigo." In Braun-Falco’s Dermatologie, Venerologie und Allergologie. Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49544-5_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ständer, Sonja. "Pruritus und Prurigo." In Braun-Falco's Dermatologie, Venerologie und Allergologie. Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-49546-9_34-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ständer, Sonja. "Pruritus und Prurigo." In Braun-Falco’s Dermatologie, Venerologie und Allergologie. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-24163-5_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ständer, Sonja, and Dieter Metze. "Pruritus and Prurigo." In Braun-Falco’s Dermatology. Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29316-3_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ständer, Sonja. "Pruritus and Prurigo." In Braun-Falco´s Dermatology. Springer Berlin Heidelberg, 2020. http://dx.doi.org/10.1007/978-3-662-58713-3_34-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fry, Lionel, Fenella T. Wojnarowska, and Parvin Shahrad. "Pruritus and Prurigo Nodularis." In Illustrated Encyclopedia of Dermatology. Springer Netherlands, 1985. http://dx.doi.org/10.1007/978-94-010-9390-3_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hölzle, E. "UV-Therapien bei Pruritus und Prurigo." In Fortschritte der praktischen Dermatologie und Venerologie. Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71732-1_79.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ikoma, Akihiko. "Neuroanatomy of Itch." In Pruritus. Springer London, 2009. http://dx.doi.org/10.1007/978-1-84882-322-8_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Misery, Laurent. "Pruritus, Pain and Other Abnormal Skin Sensations." In Pruritus. Springer London, 2009. http://dx.doi.org/10.1007/978-1-84882-322-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dalgard, Florence, and Elke Weisshaar. "The Epidemiology of Pruritus." In Pruritus. Springer London, 2009. http://dx.doi.org/10.1007/978-1-84882-322-8_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Prurits"

1

Samson, Ogundipe, Odetoye E. Temitope, and Adesina O. A. "Optimization of oil extraction from Mucuna pruriens seeds (velvet bean) for biodiesel production." In 2024 International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG). IEEE, 2024. http://dx.doi.org/10.1109/seb4sdg60871.2024.10630347.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Odeyemi, Charity Segun, Adegbenro Sunday Ajani, Mojoyinola Koforola Awodele, Ayodeji Oladiran Awodugba, and Godwin Babatunde Egbeyaleline. "Experimental Investigation on the use of Vernonia Amygdalina-Mucuna Pruriens Dye Mixture as Sensitizer in Dye-Sensitized Solar Cell." In 2024 International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG). IEEE, 2024. http://dx.doi.org/10.1109/seb4sdg60871.2024.10630432.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rallis, Efstathios, Eleni Sfyri, and Vasiliki Kefala. "Etiology of chronic pruritus." In 1st Conference of the Hellenic Scientific Society of Aesthetics. PHARMAKON-Press, 2024. http://dx.doi.org/10.61873/zefl9915.

Full text
Abstract:
Pruritus is considered a very frequent symptom and defined as chronic when its duration is longer than 6 weeks. The prevalence and the etiology of chronic pruritus (CP) are associated with various factors such as, age, atopy, underly- ing diseases, ethnicity, climate and humidity, as well as access to local healthcare system. The CP significantly affects the patients’ quality of life. Over time, patients often report sleep and mood disorders, with a negative psycho-social impact. From skin to brain, pruritus transmission occurs via multiple pathways, which are regulated by numerous cells, mediators, and receptors. A complete history and careful clinical examination are the keys to the diagnostic approach and determining treatment steps. Dermatological examination is essential and sometimes, an extensive laboratory testing must be carried out. The complexity in the presentation of this symptom, its obscure pathophysiology and multifactorial etiology, and the absence of clearly defined therapeutic goals, make CP a diagnostic and therapeutic challenge.
APA, Harvard, Vancouver, ISO, and other styles
4

DE COS, ESPERANZA, Gonzalo Tena, and Begoña García. "Estrés postraumático y prurito vulvar." In 30 Congreso Nacional de Medicina General y de Familia. Grupo Pacífico, 2024. http://dx.doi.org/10.48158/semg24-24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Martínez, María, Antonio Manuel Medina, José Manuel González, María Martínez, Bibiana Vázquez, and Andrea Ruso. "Prurito en gestante: ¿Normal o patológico?" In XXIX Congreso Nacional de Medicina General y de Familia y V Jornadas SEMG Andalucía. Grupo Pacífico, 2023. http://dx.doi.org/10.48158/semg23-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Magora, Florella, Veral Leibovici, and Sarale Cohen. "Virtual reality methodology for pruritus and pain." In 2009 Virtual Rehabilitation International Conference. IEEE, 2009. http://dx.doi.org/10.1109/icvr.2009.5174240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Georgieva, F. G. "PRURITUS IN LICHEN SIMPLEX CHRONICUS: PSYCHOLOGY OR PHYSIOLOGY." In The 4th Global Virtual Conference. Publishing Society, 2016. http://dx.doi.org/10.18638/gv.2016.4.1.745.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kremer, AE, M. Carbone, GM Hirschfield, F. Nevens, L. Muratori, and V. Leroy. "The PBC Pruritus Management Protocol: consensus of an Expert group." In 48. Jahrestagung der Gesellschaft für Gastroenterologie in Bayern e.V. Information und Programm: www.gfgb.org. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0040-1705784.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

ALMEIDA BARBOSA, GABRIELA, Robson Antônio Gonçalves, Valéria Bezerra da Silva, et al. "PRURITUS IN SYSTEMIC SCLEROSIS, A THERAPEUTIC CHALLENGE: A CASE REPORT." In SBR 2021 Congresso Brasileiro de Reumatologia. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2021.2186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sanchez Cohen, A., JB Schuitemaker Requena, VM Vargas Raidi, et al. "B213 Brachioradialis pruritus as the main symptom of cervical compressive radiculopathy." In ESRA Abstracts, 39th Annual ESRA Congress, 22–25 June 2022. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/rapm-2022-esra.288.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Prurits"

1

Ghirozi, Isadora Bueloni, Rebeka Bustamante Rocha, Heloi Jose Stefani, Yasmin Luz Lima de Mesquita, Everton Bruno Castanha, and Lais Lopes Almeida Gomes. Efficacy and safety of dupilumab for atopic dermatitis in children and adolescents. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.5.0160.

Full text
Abstract:
Review question / Objective: Is dupilumab effective for treatment of children and adolescentes with moderate to severe atopic dermatitis? Does it improve SCORAD outomes? Does it reduce pruritus? Does it improve quality of life? Does improve sleep quality? Condition being studied: Atopic dermatitis is a common and chronic skin disease characerized by inflammation, pruritus and dryness of the skin. Diminished quality of life, sleeping problems and intense chronic pruritus are among the consequences faced by patients with atopic dermatitis, especially those with moderate to severe presentations of the disease.
APA, Harvard, Vancouver, ISO, and other styles
2

Wala, Kamila, and Jacek Szepietowski. Difelikefalin in the treatment of chronic kidney disease-associated pruritus: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.5.0154.

Full text
Abstract:
Review question / Objective: The objective of this study is to evaluate the clinical efficacy and safety as well as to summarize the current knowledge of difelikefalin in treatment of patients with CKD-aP based on the available clinical trials. Condition being studied: Chronic kidney disease-associated pruritus (CKD-aP), also known as uremic pruritus, is a condition that significantly reduces the quality of life of patients with end-stage renal disease. There were unmet needs in the treatment of this condition. Difelikefalin is a novel opioid agonist with high selectivity for kappa opioid re-ceptors (KOR) that has been shown to be effective in the treatment of this type of chronic pruritus.
APA, Harvard, Vancouver, ISO, and other styles
3

Sánchez Legaza, Elena, Encarnación Antúnez Estudillo, and Rosario Guerrero Cauqui. Prurito ótico por carcinoma basocelular en conducto auditivo externo. Siicsalud.com, 2023. http://dx.doi.org/10.21840/siic/172624.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Charry Echavarrí, María Valentina, Laura Camacho Monsalve, and Santiago Pérez Gil. Diagnóstico y tratamiento de la Esclerosis Múltiple (EM). Facultad de Medicina Universidad de Antioquia, 2023. http://dx.doi.org/10.59473/medudea.pc.2023.12.

Full text
Abstract:
Paciente femenina de 36 años quien a la consulta refiere que presenta parestesias en miembro inferior derecho desde hace una semana, posteriormente acompañadas de paresia, al punto de no poder subir ni bajar escaleras. Dentro de la revisión por sistemas describe que hace aproximadamente un año había presentado prurito en la región abdominal con una distribución en banda a nivel de las últimas costillas y el epigastrio, este episodio fue autolimitado y tuvo una duración de 2 semanas.
APA, Harvard, Vancouver, ISO, and other styles
5

Qiu, Yan-Li, Jian Zu, and Yan Luo. Effect of butorphanol on morphine-related pruritus: a meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.4.0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hu, Chao, Chao Liao, Qing-Xiu Lu, et al. Efficacy and safety of acupuncture for patients with pruritus: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.8.0043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gao, Chao-qing, Jia-jun Zhou, Ya-yin Tan, and Chang-jun Tong. Effectiveness of montelukast for uremic pruritus in hemodialysis patients: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.10.0043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Jie, Xinwei Yang, Jianli Huang, Yihua Xu, and Xianbo Wu. Efficacy and safety of Chinese herbal medicine in the treatment of chronic pruritus: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.6.0103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yang, Xue, Xu Zhang, Ziru Yu, et al. Effectiveness and safety of acupuncture as a complementary therapy for skin pruritus after uremia hemodialysis: A protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.11.0112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Prurits' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography